Nexalis Therapeutics Ltd (ASX:NX1) Share Price & Analysis

Nexalis Therapeutics Ltd (ASX: NX1) is an Australian clinical-stage biopharmaceutical company headquartered in Melbourne, Victoria, specializing in the development of rapid-onset inhaled therapies. Formerly known as InhaleRx Limited, the company officially transitioned to its current name and ticker symbol in February 2026 to align with its strategic focus on advanced drug-device combinations. The entity operates within the biotechnology sector, primarily dedicated to addressing profound unmet medical needs in the global pain management and mental health markets through precision delivery systems.

The company’s operational focus is centered on a diversified pipeline of clinical assets, including IRX-211, IRX-616a, and SRX-25. IRX-211 is a non-opioid, inhaled drug-device candidate designed to treat breakthrough cancer pain, having already completed a Phase 1 clinical trial with positive safety results. Nexalis is also actively progressing IRX-616a, a cannabidiol-based aerosol delivered via a metered-dose inhaler for the treatment of panic disorder, which recently entered first-in-human trials to evaluate its pharmacokinetics and tolerability.

Nexalis Therapeutics positions itself as a high-growth biotechnology firm by leveraging the U.S. FDA’s 505(b)(2) regulatory pathway to accelerate the commercialization of its therapeutic candidates. This strategy aims to reduce development costs and timelines while targeting large addressable markets, such as the multi-billion dollar breakthrough cancer pain and anxiety sectors. By providing rapid systemic absorption and a faster onset of action than traditional oral medications, the company seeks to deliver superior clinical outcomes and a compelling value proposition for patients and healthcare providers alike.